“…Thea bility to manufacture high-potency molecules in as afer,m ore-controlled environment, often in previously unachievable purity,i sw hy this synthetic format has been embraced by pharmaceutical manufacturers,a nd deemed by the United States Food and Drug Administration (USFDA) as an emerging technology that will lead pharmaceutical modernization in the future. [1][2][3][4][5] Thed ynamic nature of CM, which comprises av ariety of moving mechanical components,f orces manufacturers to thoroughly understand process dynamics as af unction of various feed attributes (purity of raw materials,m aterial flow properties,e tc. ), transformation conditions (mass-and energy-transfer behaviors,l aminar versus turbulent flow,e tc.…”